Jessica Hassel

53PUBLICATIONS
226CO-AUTHORS
Molecular targetsTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (53)

|Aug 11, 2026
Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

|Jun 25, 2026
Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma.

|Apr 27, 2026
Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse Events.

|Apr 21, 2026
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

|Mar 14, 2026
Mycophenolate Mofetil for Treatment of Ipilimumab-Induced Colitis in Patients with Metastatic Melanoma.

Christina Naoum, Julia K Winkler, Pawel Majenka

|Mar 05, 2026
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study.

Elizabeth M Gaughan, Miso Kim, Ignacio Mendez

Pageof 9

Frequent Collaborators

11 joint publications

Ralf Gutzmer

8 joint publications

Dirk Schadendorf

7 joint publications

Christoffer Gebhardt

6 joint publications

Selma Ugurel